Effect of Pharmaceutical Interventions Targeting Thromboxane Receptors and Thromboxane Synthase in Cardiovascular and Renal DiseasesKjell S. Sakaríassen, Alexandra Santana Sorensen, Henri Bounameaux et al.|Future Cardiology|2009Cited by 26
The dual thromboxane receptor antagonist and thromboxane synthase inhibitor EV‐077 is a more potent inhibitor of platelet function than aspirinPierre Fontana, Alexandra Santana Sorensen, Jon‐Paul Meyer et al.|Journal of Thrombosis and Haemostasis|2011Cited by 18
EV-077 in vitro inhibits platelet aggregation in type-2 diabetics on aspirinKjell S. Sakaríassen, Rodolfo Pedro Rothlin, Eti Alessandra Femia et al.|Thrombosis Research|2012Cited by 17
Single ascending oral dose pharmacokinetics and pharmacodynamics study of EV-077: the specific inhibitor of prostanoid- and isoprostane-induced cellular activationA. Richardson, Alexandra Santana Sorensen, Kjell S. Sakaríassen et al.|European Journal of Clinical Pharmacology|2012Cited by 8
A micro‐method for lipoprotein cholesterol profiles: Impact of CETP in KKA <sup>y</sup> micePēteris Alberts, Kjell S. Sakaríassen, Vibeke Arrhenius‐Nyberg et al.|European Journal of Lipid Science and Technology|2006Cited by 1